13.09.2019
- Mallinckrodt has agreed to sell its wholly owned subsidiary BioVectra to an affiliate of private equity group H.I.G. Capital for $250 million. The price includes a fixed sum of...
12.12.2018
- Mallinckrodt Pharmaceuticals, the UK-domiciled, US-focused specialty drugmaker, plans to break up into two differentiated companies, with one focused on innovative specialty...
05.01.2018
- Specialty pharmaceuticals manufacturer Mallinckrodt has agreed to buy biopharmaceuticals producer Sucampo, including its commercial and development assets. The transaction is...
13.08.2015
- Irish drugmaker Mallinckrodt said it plans to acquire US immunotherapy company Therakos for $1.33 billion from American private equity investor Gores Group. The deal is planned to...
